Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Axsome Therapeutics, Inc.

https://axsome.com/

Latest From Axsome Therapeutics, Inc.

Delay Looms For Axsome Therapeutics’ Entry Into Major Depressive Disorder Market With Lead Product

Axsome Therapeutics’ lead candidate, AXS-05, was nearing the US market for major depressive disorder, but the US company is trying to find out more about deficiencies identified by US regulators; the biotech has also reported positive Phase II results in treatment-resistant depression.

Neurology Approvals

T-knife Taps Into Investor Interest in T-Cell Receptor Therapies

The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.

Financing Cancer

ADDF’s Fillit On FDA’s Tough Aducanumab Decision, Advances In Alzheimer’s

The pending US FDA decision on Biogen’s drug overshadows progress in Alzheimer’s diagnosis, symptomatic treatments and the need to keep studying anti-tau therapies after Roche’s setback.

Neurology Innovation

Keeping Track: The Breakthrough Designations Of Summer Eschew Phase I

The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Review Pathway
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register